BULL CITY BIOBUCKS
Join us for a fireside chat with Tavros Therapeutics who signed a $930M deal with Bayer in October 2022 on only $3M in equity financing. How the F$#% did they do that? Eoin McDonnell, CEO of Tavros, will breakdown the inner workings of engineering a successful major pharmaceutical partnership.